As FOXO3a was more strongly expressed in ER+ breast cancer cells (MCF7 and T47D) than in TNBC cells (MDA-MB-231 and BT549) (Fig. 1a, b), we then investigated whether downregulation of FOXO3a plays a key role in BCSC properties. Here, FOXO3 is linked to breast cancer.